This paper argues that AI-mediated omission of contraindications constitutes a post-market safety risk that is currently under-monitored by pharmaceutical manufacturers. Using a reconstructed illustrative scenario, the paper demonstrates how Reasoning Claim Tokens (RCTs) can function as evidentiary artifacts to detect, document, and audit such omissions without requiring access to AI model internals or operational control over third-party systems.